FDA-approved surgical aortic valve implanted for first time in US
A team of surgeons made a bit of history when they performed the first U.S. implant of a Corcym’s next-generation surgical aortic heart valve, the Perceval Plus LANCELOT. The procedure, performed in September 2025, was a success, and the patient fully recovered.
Cardiac surgeons have been implanting Corcym’s Perceval Plus valve for many years Its sutureless, collapsible frame was built to simplify surgical aortic valve replacement (SAVR) procedures and help patients recover faster. In May 2025, Corcym secured U.S. Food and Drug Administration approval for this newer version of the Perceval Plus device, the Perceval Plus LANCELOT, that includes a few key updates: laser-cut leaflets and thread holes for improved consistency and a zero-pressure fixation process that reduces stress on the leaflets.
Robert Gallegos, MD, PhD, chief of cardiac surgery at CHI Health, called the updated valve “an important step forward” for the treatment of patients with aortic valve disease.
“Innovations like this can help surgeons perform procedures efficiently while supporting strong valve performance and long-term outcomes for patients,” Gallegos said.
Image courtesy of Corcym.
“This kind of innovation reflects the continued evolution of sutureless surgical valve therapy,” added Ali J. Khiabani, MD, a cardiac surgeon at CHI Health. “Precision in valve design may help improve how the valve functions, potentially improving blood flow and gradients across the valve, and ultimately better long-term outcomes for patients undergoing bioprosthetic aortic valve replacement.”
Corcym, a global medtech company solely focused on cardiac surgery technologies, first launched in 2021 after the company LivaNova was acquired by Gyrus Capital, an investment firm. The company makes a variety of valves for SAVR and other cardiac procedures.
“At Corcym, innovation begins and ends with the patient,” Christian Mazzi, CEO of Corcym, said in the same statement. “The first U.S. implantation of our Perceval Plus LANCELOT valve reflects our commitment to advancing surgical technologies that support cardiac surgeons and improve outcomes for patients with structural heart disease.”
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.